Quick Answer
Axsome Therapeutics, Inc. reported Operating Income of -$166.76 million for fiscal year 2025.
Axsome Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$166.76M | +40.6% |
| 2024 | -$280.56M | -21.0% |
| 2023 | -$231.82M | -28.9% |
| 2022 | -$179.80M | -44.2% |
| 2021 | -$124.71M | -25.8% |
| 2020 | -$99.14M | -47.4% |
| 2019 | -$67.25M | -104.7% |
| 2018 | -$32.85M | -20.9% |
| 2017 | -$27.16M | +1.4% |
| 2016 | -$27.54M | -199.5% |
| 2015 | -$9.20M | -62.1% |
| 2014 | -$5.67M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$46.11M | +26.4% | -25.6% |
| June 30, 2025 | -$36.71M | +53.0% | +35.6% |
| March 31, 2025 | -$56.98M | +15.3% | +9.0% |
| September 30, 2024 | -$62.62M | -0.8% | +19.8% |
| June 30, 2024 | -$78.05M | -20.0% | -16.0% |
| March 31, 2024 | -$67.28M | -955.5% | -8.3% |
| September 30, 2023 | -$62.12M | -46.5% | +4.5% |
| June 30, 2023 | -$65.06M | -66.0% | -920.7% |
- Axsome Therapeutics, Inc. showed an increase of +40.6% in Operating Income compared to the prior fiscal year.
- Over the 2014–2025 period, Axsome Therapeutics, Inc.’s operating income has declined by 2840.1% (from -$5.67 million to -$166.76 million).
- The most recent figure is from Axsome Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: